Business
Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
BEDFORD, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes
About this update from Lantheus Holdings, Inc.
[{"type":"text","content":"BEDFORD, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced it will present piflufolastat F 18 data at the upcoming 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place February 16-18, 2023, in San Francisco, CA. Piflufolastat F 18 is a PSMA-targeted radiopharmaceutical approved in the U.S. for imaging prostate cancer patients both at the time of initial staging and at disease recurrence. “Earlier investigation with piflufolastat F 18 PSMA PET/CT in men with biochemically recurrent prostate cancer reported a change in recommended management for nearly two out of three men based on the scan results,” said Bela S. Denes, MD, Vice President, Global Medical Affairs, Lantheus. “This study expanded on those findings focusing specifically on the impact and utility of scanning men with very low PSA levels. We look forward to detailing the data at this month’s ASCO GU conference.” Presentation details are as follows: Date & Time: February 16, 2023, 11:30am – 1:00pm; 5:45pm – 6:45pm PTSession Title: Poster Session A: Prostate CancerTitle: Changes in planned disease management after piflufolastat F 18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: a secondary analysis from the CONDOR studyPresenter: Dr. Frederic PouliotAbstract Number: 61 The abstract will be available on meetinglibrary.asco.org February 13. PYLARIFY® (piflufolastat F 18) InjectionIndicationPYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: • with suspected metastasis who are candidates for initial definitive therapy. • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Important Safety InformationContraindicationsNone. Warnings and PrecautionsRisk of Image MisinterpretationImaging interpretation errors can occur with PYLARIFY imaging. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate can...